WHAT FACTORS AFFECT LONG-TERM SURVIVAL AFTER RESPONDING TO GEFITINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER? REAL WORLD EVIDENCE

被引：0
|
作者：
Takahashi, R. [1 ]
Imamura, F. [2 ]
Morita, S. [3 ]
Mori, M.
Komuta, K. [4 ]
Kijima, T. [1 ]
Namba, Y.
Nishino, K. [2 ]
Yamamoto, S. [4 ]
Hirata, H. [1 ]
Tachibana, I. [1 ]
Kumanogoh, A. [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka 565, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan
[3] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa, Japan
[4] Osaka Police Hosp, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：137 / 137
页数：1
相关论文
共 50 条
  • [1] What factors affect long-term survival after responding to gefitinib in advanced non-small cell lung cancer? Real-world evidence
    Takeuchi, Yoshiko
    Imamura, Fumio
    Morita, Satoshi
    Mori, Masahide
    Komuta, Kiyoshi
    Kijima, Takashi
    Namba, Yoshinobu
    Nishino, Kazumi
    Yamamoto, Suguru
    Takahashi, Ryo
    Nakazawa, Yukie
    Minami, Seigo
    Ogata, Yoshitaka
    Kumanogoh, Atsushi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
    Molinier, O.
    Besse, B.
    Barlesi, F.
    Audigier-Valette, C.
    Friard, S.
    Monnet, I
    Jeannin, G.
    Mazieres, J.
    Cadranel, J.
    Hureaux, J.
    Hilgers, W.
    Quoix, E.
    Coudert, B.
    Moro-Sibilot, D.
    Fauchon, E.
    Westeel, V
    Brun, P.
    Langlais, A.
    Morin, F.
    Souquet, P. J.
    Girard, N.
    [J]. ESMO OPEN, 2022, 7 (01)
  • [3] A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization
    Kroman, Niels
    Ejlertsen, Bent
    Jensen, Maj-Britt
    Wohlfahrt, Jan
    [J]. ACTA ONCOLOGICA, 2009, 48 (03) : 471 - 471
  • [4] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
    Zheng-Tao Zhou
    Xin-Hua Xu
    Qing Wei
    Ming-qian Lu
    Jie Wang
    Cai-Hong Wen
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 64 : 1123 - 1127
  • [5] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
    Zhou, Zheng-Tao
    Xu, Xin-Hua
    Wei, Qing
    Lu, Ming-qian
    Wang, Jie
    Wen, Cai-Hong
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1123 - 1127
  • [6] Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer
    Remon, Jordi
    Hendriks, Lizza E. L.
    Besse, Benjamin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2321 - +
  • [7] Gefitinib in the treatment of advanced non-small-cell lung cancer
    Reck, Martin
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 401 - 412
  • [8] Gefitinib for refractory advanced non-small-cell lung cancer
    Moriguchi, H
    Kim, TY
    Sato, C
    [J]. LANCET, 2006, 367 (9507): : 299 - 300
  • [9] Gefitinib or docetaxel in advanced non-small-cell lung cancer
    Cullen, Michael
    Thatcher, Nicholas
    [J]. LANCET, 2008, 372 (9652): : 1785 - 1786
  • [10] Gefitinib therapy for advanced non-small-cell lung cancer
    Liu, CY
    Seen, S
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (11) : 1644 - 1653
12345